Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

Malcikova J, Razga F, Jurcek T, Dvorakova D, Zackova D, Toskova M, Sebejova L, Smardova J, Oltova A, Vankova G, Jurackova L, Trbusek M, Pospisilova S, Mayer J, Racil Z.

Leuk Lymphoma. 2013 Sep;54(9):2083-7. doi: 10.3109/10428194.2012.762649. Epub 2013 Feb 1. No abstract available.

PMID:
23289360
2.

BCR-ABL1 compound mutations drive ponatinib resistance.

[No authors listed]

Cancer Discov. 2014 Nov;4(11):OF13. doi: 10.1158/2159-8290.CD-RW2014-186. Epub 2014 Sep 4.

3.

Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.

Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H.

Acta Haematol. 2012;127(1):34-42. doi: 10.1159/000331472. Epub 2011 Oct 14.

PMID:
22005133
4.

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le Coutre P.

Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.

5.

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Patel AB, O'Hare T, Deininger MW.

Hematol Oncol Clin North Am. 2017 Aug;31(4):589-612. doi: 10.1016/j.hoc.2017.04.007. Review.

6.

[Chronic myelogenous leukemia: diagnosis and treatment].

Demeter J, Poros A, Bödör C, Horváth L, Masszi T.

Orv Hetil. 2016 Sep;157(37):1459-68. doi: 10.1556/650.2016.30521. Hungarian.

PMID:
27615196
7.

Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, Haferlach C, Haferlach T.

Haematologica. 2016 Jul;101(7):830-8. doi: 10.3324/haematol.2016.145888. Epub 2016 Apr 21.

8.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.

Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.

Clin Cancer Res. 2017 May 1;23(9):2289-2300. doi: 10.1158/1078-0432.CCR-16-1930. Epub 2016 Nov 17.

9.

Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.

Akram AM, Iqbal Z, Akhtar T, Khalid AM, Sabar MF, Qazi MH, Aziz Z, Sajid N, Aleem A, Rasool M, Asif M, Aloraibi S, Aljamaan K, Iqbal M.

Cancer Biol Ther. 2017 Apr 3;18(4):214-221. doi: 10.1080/15384047.2017.1294289. Epub 2017 Feb 21.

10.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
11.

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.

Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Müller MC, Radich JP, Shah NP.

Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23. Review.

12.

Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.

Moore FR, Yang F, Press RD.

Methods Mol Biol. 2013;999:25-39. doi: 10.1007/978-1-62703-357-2_2.

PMID:
23666688
13.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J.

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

PMID:
19768693
14.

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J.

Blood. 2012 Oct 18;120(16):3382-3. doi: 10.1182/blood-2012-04-424192. No abstract available.

15.

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM.

Cancer. 2011 May 1;117(9):1800-11. doi: 10.1002/cncr.25717. Epub 2010 Nov 29. Review. Erratum in: Cancer. 2011 Aug;117(15):3535.

16.

HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.

Cancer Lett. 2014 Jun 28;348(1-2):50-60. doi: 10.1016/j.canlet.2014.03.012. Epub 2014 Mar 18.

PMID:
24657654
17.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

18.

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW, Wennerberg K.

Nature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.

PMID:
25686603
19.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

20.

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP.

Blood. 2010 Feb 4;115(5):1049-53. doi: 10.1182/blood-2009-03-210377. Epub 2009 Dec 2. Erratum in: Blood. 2010 May 13;115(19):4006. Thoenissen, Nils H [corrected to Thoennissen, Nils H].

Supplemental Content

Support Center